A one-shot vaccine option made by Johnson & Johnson could be out soon after the company asked regulators to clear it for public use.

Whether the shot receives authorization should be known in three weeks, when an independent FDA panel is scheduled to review the data and make a recommendation.

Johnson & Johnson's vaccine has shown it is 66% effective at preventing symptomatic COVID-19, and 85% effective at stopping severe illness.

That's not the 95% seen from Pfizer and Moderna, but Rockville Centre Pharmacy's Howard Jacobson says it's still more than enough to have an impact.

"85, 95, listen we've got to get people vaccinated. That's the most important thing. Nobody knows if this vaccine is going to last three months, six months, a year, a lifetime," says Jacobson. "There are unknowns, but I still think it's ultra-important to get people vaccinated and let people see there is very little downside."

At Jacobson's Hempstead Avenue pharmacy, a constant stream of people has been coming through the door to get vaccinated. He says demand is so high that appointments are typically gone after just a few minutes.

The pharmacy administers more than 100 doses of the Moderna vaccine each week -- not enough to keep up with demand. But Johnson & Johnson's vaccine could provide much-needed reinforcements.

Outside of it being one-shot and its efficacy, the Johnson & Johnson shot offers more convenience because it does not need to be stored at ultra-cold temperatures.

If approved, the company says it could deliver 100 million doses to the U.S. by June.